Search clinical trials for: AZD2927

Total 44 results

AstraZeneca

Completed

A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients

Arrhythmia

Sweden, Norway
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

Healthy

Sweden
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Germany
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
AstraZeneca
Parexel

Withdrawn

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

Heart Failure
AstraZeneca

Completed

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

Healthy

United States
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers

Healthy

United Kingdom
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
AstraZeneca

Completed

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Anxious Major Depressive Disorder

United States
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers (ADME)

Neuroscience

United Kingdom
AstraZeneca
Parexel

Recruiting

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (Re-PHIRE)

Heart Failure | Pulmonary Hypertension (World Health Organization Group 2)

Netherlands, Spain, Japan, Germany, Austria, Italy, China, Sweden, United Kingdom, United States, Poland, Czechia, Denmark, Canada
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers (SAD)

Healthy Volunteers

Germany
AstraZeneca
Parexel

Completed

A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Cardiovascular Disease

United Kingdom
AstraZeneca

Completed

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Heart Failure

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses

Healthy

United Kingdom
AstraZeneca

Completed

AZD2624 Multiple Ascending Dose Study in Japan (JMAD)

Healthy | Safety

Japan
AstraZeneca

Terminated

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

Obesity

United Kingdom
AstraZeneca

Completed

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Heart Failure

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

Heart Failure

United Kingdom
AstraZeneca
Parexel

Completed

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..

Nerve Pain

Sweden, Bulgaria, France, Russian Federation, United Kingdom, Poland, Denmark
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers

Healthy

Japan
AstraZeneca

Completed

AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy Volunteer

United Kingdom
AstraZeneca

Completed

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

Neuropathic Pain

United States, Canada
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid (PET)

Alzheimer´s Disease

Sweden
University Health Network, Toronto
AstraZeneca; NeoGenomics Laboratories

Recruiting

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Canada
AstraZeneca

Completed

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Healthy Subjects | Pharmacodynamics

United Kingdom
AstraZeneca

Completed

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease (MIRACLE)

Heart Failure | Chronic Kidney Disease

United States, Germany, Italy, Spain, Belgium, Denmark, Thailand, Poland, Canada, Korea, Republic of, Slovakia, Taiwan, Turkey, Ukraine, Japan, Czechia, Hungary, Bulgaria, Russian Federation, Sweden, Lithuania, India
AstraZeneca
Daiichi Sankyo

Recruiting

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

Advanced or Metastatic NSCLC

United States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Italy, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
AstraZeneca

Terminated

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

Heart Failure

Czechia, Bulgaria, Poland, United Kingdom
Presage Biosciences
Merck Sharp & Dohme LLC

Recruiting

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Solid Tumor

United States
Presage Biosciences
AstraZeneca

Not yet recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
AstraZeneca

Completed

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca

Completed

Phase IIA Study in Patients With Schizophrenia

Schizophrenia

United States
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03)

Gastric Cancer

China, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland

3

Subscribe